-
Mashup Score: 0
After its Biologics License Application was rejected by the FDA, BrainStorm’s Phase III data suggest its amyotrophic lateral sclerosis candidate significantly lowers neurofilament light chain levels.
Source: BioSpaceCategories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 5Expanding ALS Trial Eligibility Could Benefit Patients, Therapeutic Progress | BioSpace - 1 year(s) ago
The majority of ALS patients are excluded from clinical trials. Experts say using biomarkers and stratifying trial populations can expand eligibility and provide additional scientific insights.
Source: BioSpaceCategories: Latest Headlines, Rare DiseaseTweet-
https://t.co/emljZedETC
-
-
Mashup Score: 0AstraZeneca Halts Phase II Asthma Trial Due to Safety Findings in Toxicology Study | BioSpace - 1 year(s) ago
Pieris Pharmaceuticals announced partner AstraZeneca’s decision to discontinue clinical studies of elarekibep, an inhaled IL-4 receptor alpha inhibitor, based on a non-clinical toxicology study.
Source: BioSpaceCategories: Healthcare Professionals, Latest HeadlinesTweet-
https://t.co/Ag7jk8qpeb
-
-
Mashup Score: 0
Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma – read this article along with other careers information, tips and advice on BioSpace
Source: BioSpaceCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 NEWS 🚨 @US_FDA lift their clinical hold of the phase I trial of MT-0169 for the treatment of extramedullary multiple #myeloma. This partial clinical hold was implemented to review safety data following the incidence of 2 cardiac AEs. https://t.co/4EyBdVtZkn #mednews #mmsm https://t.co/cCCpJZT8XE
-
-
Mashup Score: 0Grail Expands Blood Test to Symptomatic Patients, Aims to Revolutionize Cancer Diagnosis | BioSpace - 1 year(s) ago
Grail, the blood testing company, explores the potential of its commercial blood test, Galleri, in detecting cancer symptoms.
Source: BioSpaceCategories: Cardiologists, Latest HeadlinesTweet-
https://t.co/Qvogx4zgX8 To put things in perspective, compare performance of GRAIL test for cancer detection with the best we have for CVD detection (CAC score). Is it too good to be true? https://t.co/ZleNzynP2G
-
-
Mashup Score: 0
Preliminary trial results show the GSK five-in-one meningitis vaccine is immunologically effective against the most common strains, as the FDA decision date for Pfizer’s candidate looms.
Source: BioSpaceCategories: Infectious Disease, Latest HeadlinesTweet-
“The vaccine is designed as a single injection intended for healthy adolescents and adults 10–25 years old.” https://t.co/YDYt9sNvP5
-
-
Mashup Score: 0
The regulator in a Complete Response Letter rejected ImmunityBio’s bladder cancer hopeful due to deficiencies with the company’s third-party contract manufacturer.
Source: BioSpaceCategories: Hem/Oncs, Latest HeadlinesTweet-
Anktiva got CRL! https://t.co/ZRKGtrA5Pg
-
-
Mashup Score: 1AACR Highlights the Potential of Cancer Vaccines | BioSpace - 2 year(s) ago
Cancer vaccines enjoyed a moment in the spotlight this week as Moderna, Merck, Nykode Therapeutics and Transgene shared promising updates at AACR and beyond.
Source: BioSpaceCategories: Healthcare Professionals, Latest HeadlinesTweet-
https://t.co/CkXnWXeFDG
-
-
Mashup Score: 0World Vaccine Congress Panel Highlights Exigency of AMR Global Health Crisis | BioSpace - 2 year(s) ago
At the World Vaccine Congress, antimicrobial resistance as a global health crisis grabbed top billing. AMR is a global health crisis that puts the highest burden on geographies and populations with the most limited resources.
Source: BioSpaceCategories: Infectious Disease, Latest HeadlinesTweet-
“Novel antibiotics, monoclonal antibodies, microbiota [and] diagnostic tools … can play a role with vaccination.” https://t.co/u0kJiToBTn
-
-
Mashup Score: 0HUTCHMED Completes FDA Submission for High-Potential Colorectal Cancer Drug | BioSpace - 2 year(s) ago
HUTCHMED has completed the rolling submission of its New Drug Application to the FDA for fruquintinib, its candidate for refractor metastatic colorectal cancer.
Source: BioSpaceCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Learn how a study led by our Dr. Arvind Dasari of fruquintinib's potential to address a critical unmet need in refractory metastatic CRC supported HUTCHMED's FDA submission of the drug. https://t.co/Hckuifvdd0 @adasarimd @biospace #EndCancer
-
BrainStorm Touts Biomarker Data for ALS Candidate After Two FDA Rebuffs | BioSpace https://t.co/ayxF6y24io #jobs